These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 17287448)

  • 1. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.
    Fleisher AS; Sowell BB; Taylor C; Gamst AC; Petersen RC; Thal LJ;
    Neurology; 2007 May; 68(19):1588-95. PubMed ID: 17287448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.
    Fleisher AS; Sun S; Taylor C; Ward CP; Gamst AC; Petersen RC; Jack CR; Aisen PS; Thal LJ
    Neurology; 2008 Jan; 70(3):191-9. PubMed ID: 18195264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia.
    van Straaten EC; Harvey D; Scheltens P; Barkhof F; Petersen RC; Thal LJ; Jack CR; DeCarli C;
    J Neurol; 2008 Sep; 255(9):1302-8. PubMed ID: 18825439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment.
    Whitehair DC; Sherzai A; Emond J; Raman R; Aisen PS; Petersen RC; Fleisher AS;
    Alzheimers Dement; 2010 Sep; 6(5):412-9. PubMed ID: 20813342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
    De Beaumont L; Pelleieux S; Lamarre-Théroux L; Dea D; Poirier J;
    J Alzheimers Dis; 2016 Oct; 54(3):913-922. PubMed ID: 27567841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin E and donepezil for the treatment of mild cognitive impairment.
    Petersen RC; Thomas RG; Grundman M; Bennett D; Doody R; Ferris S; Galasko D; Jin S; Kaye J; Levey A; Pfeiffer E; Sano M; van Dyck CH; Thal LJ;
    N Engl J Med; 2005 Jun; 352(23):2379-88. PubMed ID: 15829527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donepezil versus vitamin E in Alzheimer's disease: Part 2: mild versus moderate-severe Alzheimer's disease.
    Onofrj M; Thomas A; Luciano AL; Iacono D; Di Rollo A; D'Andreamatteo G; Di Iorio A
    Clin Neuropharmacol; 2002; 25(4):207-15. PubMed ID: 12151908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donepezil delays progression to AD in MCI subjects with depressive symptoms.
    Lu PH; Edland SD; Teng E; Tingus K; Petersen RC; Cummings JL;
    Neurology; 2009 Jun; 72(24):2115-21. PubMed ID: 19528519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of Alzheimer disease assessment scale-cognitive part in predicting progress for amnestic mild cognitive impairment to Alzheimer disease.
    Rozzini L; Vicini Chilovi B; Bertoletti E; Conti M; Delrio I; Trabucchi M; Padovani A
    J Geriatr Psychiatry Neurol; 2008 Dec; 21(4):261-7. PubMed ID: 19017783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
    Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
    J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study.
    Sarazin M; Berr C; De Rotrou J; Fabrigoule C; Pasquier F; Legrain S; Michel B; Puel M; Volteau M; Touchon J; Verny M; Dubois B
    Neurology; 2007 Nov; 69(19):1859-67. PubMed ID: 17984454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
    Kudoh C; Arita R; Honda M; Kishi T; Komatsu Y; Asou H; Mimura M
    Psychogeriatrics; 2016 Mar; 16(2):85-92. PubMed ID: 25918972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive predictors of donepezil therapy response in Alzheimer disease.
    Saumier D; Murtha S; Bergman H; Phillips N; Whitehead V; Chertkow H
    Dement Geriatr Cogn Disord; 2007; 24(1):28-35. PubMed ID: 17495473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hard Test Your Memory. Evaluation of a short cognitive test to detect mild Alzheimer's disease and amnestic mild cognitive impairment.
    Brown JM; Wiggins J; Dong H; Harvey R; Richardson F; Hunter K; Dawson K; Parker RA
    Int J Geriatr Psychiatry; 2014 Mar; 29(3):272-80. PubMed ID: 23929807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease.
    Waring JF; Tang Q; Robieson WZ; King DP; Das U; Dubow J; Dutta S; Marek GJ; Gault LM
    J Alzheimers Dis; 2015; 47(1):137-48. PubMed ID: 26402762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment.
    Tabert MH; Manly JJ; Liu X; Pelton GH; Rosenblum S; Jacobs M; Zamora D; Goodkind M; Bell K; Stern Y; Devanand DP
    Arch Gen Psychiatry; 2006 Aug; 63(8):916-24. PubMed ID: 16894068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 'Framingham-like' Algorithm for Predicting 4-Year Risk of Progression to Amnestic Mild Cognitive Impairment or Alzheimer's Disease Using Multidomain Information.
    Steenland K; Zhao L; John SE; Goldstein FC; Levey A; Alvaro A;
    J Alzheimers Dis; 2018; 63(4):1383-1393. PubMed ID: 29843232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
    Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
    Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
    Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
    Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.